Table 2.
Reference range of percentages of T lymphocyte subsets in different age groups
| Parameters | All | (18–44) years | (45–65) years | >65years | |
|---|---|---|---|---|---|
| n = 309 | n = 101 | n = 106 | n = 102 | ||
| Age | Mean±SD | 50.52 ± 18.00 | 30.73 ± 6.52 | 54.63 ± 6.37 | 73.59 ± 6.60 |
| Sex | Male:female | 171:138 | 56:45 | 56:50 | 59:43 |
| CD3+%lymphocyte cells | Median | 67.90% | 68.5% | 66.55% | 64.2% |
| Reference range Cl 90% | (49.58–79%) | (55.33–79.28%) | (50.06–78.53%) | (48.52%–81.26%) | |
| CD3+CD4+%CD3+ | Median | 52.8% | 50.4% | 53.95% | 57.05% |
| Reference range Cl 90% | (37%–68.34) | (34.6–65.46%) | (41.85%–69.49%) | (35.43%–71.17%) | |
| CD3+CD4+%lymphocyte cells | Median | 34.1% | 32.35% | 35.05% | 35.1% |
| Reference range Cl 90% | (23.86–47.86%) | (23.7–45.81%) | (25.64–48.49%) | (19.36–50.13%) | |
| CD4+Tn%CD3+CD4+ | Median | 4.3% | 6% | 3.45% | 2.6% |
| Reference range Cl 90% | (1–10.82%) | (2.14–11.62%) | (1.1–11.16%) | (0.52–7.09%) | |
| CD4+Tscm%CD3+CD4+ | Median | 17.6 | 26.35 | 13.55 | 11.4 |
| Reference range Cl 90% | (3.3–38.94%) | (8.34–41.30%) | (3.3–35.77%) | (2.02–30.55%) | |
| CD4+Tcm%CD3+CD4+ | Median | 27.00% | 26.1% | 28.1% | 26.45% |
| Reference range Cl 90% | (14.7–43.42%) | (11.41–38.13%) | (16.37–43.20%) | (14.81–52.9%) | |
| CD4+Tem%CD3+CD4+ | Median | 20.3% | 17.6% | 22.1% | 20.85% |
| Reference range Cl 90% | (10.48–40.2%) | (8.03–34.67%) | (10.88–42.27%) | (10.27–42.41) | |
| CD4+Tte%CD3+CD4+ | Median | 0.4% | 0.5% | 0.4% | 0.7% |
| Reference range Cl 90% | (0.01–9.06%) | (0.01–10.24%) | (0.01–8.58%) | (0.01–10.7%) | |
| CD3+CD8+%CD3+ | Median | 36.8% | 38% | 35.3% | 34.8% |
| Reference range Cl 90% | (23–51.44%) | (25.13–53.70%) | (22.98–48.7%) | (18.25–57.71%) | |
| CD3+CD8+%Lymphocyte cells | Median | 24.9% | 26.15% | 22.85% | 20.85% |
| Reference range Cl 90% | (13.1–37.42%) | (16.56–40.02%) | (13.38–35.17%) | (10.39–37.97%) | |
| CD8+Tn%CD3+CD8+ | Median | 3.2% | 6.45% | 2.5% | 0.8% |
| Reference range Cl 90% | (0.3–9.34%) | (2.05–10.33%) | (0.5–8.02%) | (0.11–4.75%) | |
| CD8+Tscm%CD3+CD8+ | Median | 13.7% | 28.05% | 11.6% | 6.1% |
| Reference range Cl 90% | (1.9–38.42%) | (8.30–48.90%) | (2.67–31.81%) | (1.3–21.86%) | |
| CD8+Tcm%CD3+CD8+ | Median | 8.9% | 7.4% | 8.8% | 12.15% |
| Reference range Cl 90% | (3.38–21.04%) | (2.73–15.05%) | (3.41–21.46%) | (4.91–27.45%) | |
| CD8+Tem%CD3+CD8+ | Median | 22.8% | 22.3% | 21.35% | 27.45% |
| Reference range Cl 90% | (6–48.8%) | (5.49–37.72%) | (6.94–49.84%) | (4.91–27.45%) | |
| CD8+Tte%CD3+CD8+ | Median | 12.2% | 10.5% | 13.85% | 10.6% |
| Reference range Cl 90% | (1.9–38.42%) | (2.00–30.62%) | (1.77–39.05%) | (1.47–45.85%) | |